SM Kukil에스엠국일
078130 · KOSDAQ · ₩078130 · 에스엠국일
What brokers say about SM Kukil
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
SM Kukil is loss-making on a trailing basis, with a merger, CEO change and short-term borrowing decisions filed in recent months.
Kukil is a Korean specialty paper maker, mainly for tobacco-related and interlining paper, with an early-stage graphene subsidiary that has no product sales yet. Over the last twelve months to H1 2026 it reported revenue of about ₩62.7B, an operating loss of ₩1.3B and a net loss of ₩3.9B. The share price closed at ₩3,515 on 2026-10-23, down 18.1% over one year and about 41% below the 52-week high.
What stands out
- Trailing revenue of ₩62.7B is below 2025's ₩67.8B, and the trailing net margin is -6.2%.
- Losses have narrowed from 2023 and 2024, when operating margins were -9.2% and -2.3%, but the company has not been profitable in the years shown.
- Cash of ₩16.0B is reported, the liabilities-to-equity ratio is 9.8%, and no borrowings figure is given in the data.
- Price-to-book is 3.3, while P/E is not meaningful because earnings are negative; the company pays no dividend.
- Foreign ownership is 0%, and 20-day flows were net retail selling of about ₩1.8B, with institutions net buying about ₩1.2B.
What to watch
- Filings show a merger decision (September 2026), an amended merger attachment, a shareholders' meeting and a record date, so the terms and timing of the merger matter.
- An October 2026 decision on increasing short-term borrowings and a 'major management matter' filing are not explained in the data and should be checked in the full filings.
- Whether graphene development reaches commercial sales, since none is recorded yet; no news headlines were available in the data.
Data as of Oct 23, 2026 · written 5d ago
This is not financial advice.
Also known as: SM Kukil / 에스엠국일 / 078130 / KRX:078130
Source: KRX statistical information